Simple Summary Apoptosis, a programmed form of cell death, represents the main
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …

Simple Summary Prostate cancer treatment has improved over the last 20 years; despite
this, approximately 33,000 men died from the disease in the United States in 2020. In view of …

Loss-of-function mutations in KMT2D are a striking feature of germinal center (GC)
lymphomas, resulting in decreased histone 3 lysine 4 (H3K4) methylation and altered gene …

Purpose: Bcl-2 has been effectively targeted in lymphoid malignancies. However, resistance
is inevitable, and novel approaches to target mitochondrial apoptosis are necessary …

Homoharringtonine (HHT), an approved anti-leukemic alkaloid, has been reported
effectively in many types of tumor cells. However, its effect on melanoma cells has not been …

Background The BCL2 inhibitor venetoclax has shown efficacy in several hematologic
malignancies, with the greatest response rates in indolent blood cancers such as chronic …

Hematologic malignancies (HM) comprise diverse cancers of lymphoid and myeloid origin,
including lymphomas (approx. 40%), chronic lymphocytic leukemia (CLL, approx. 15%) …

Simple Summary Diffuse large B cell lymphoma (DLBCL) is the most common type of non-
Hodgkin lymphoma (NHL). Despite the genetic heterogeneity of the disease, most patients …

Background Existing research shows that ABT-199, as a first-line drug, have been widely
used in hematological malignancies, especially in leukemia, but the clinical efficacy of single …

Simple Summary The BCL2 protein is expressed in many non-Hodgkin lymphomas (NHLs)
as well as associated leukemias, eg, chronic lymphocytic leukemia (CLL). It functions as a …